首页> 外文会议>International Congress on Coronary Artery Disease >PCSK9 polymorphism rs505151 affects lipid-lowering response to atorvastatin but does not influence ezetimibe therapy in Chilean subjects
【24h】

PCSK9 polymorphism rs505151 affects lipid-lowering response to atorvastatin but does not influence ezetimibe therapy in Chilean subjects

机译:PCSK9多态性RS505151影响到阿托伐他汀的降脂响应,但不会影响智利受试者的ezetimibe治疗

获取原文

摘要

PCSK9 is a key regulator of LDL-C, enhancing degradation of hepatic LDLr. Several gain-of-function and loss-of-function mutations in PCSK9 have been linked to hypercholesterolemia (HC) and hypocholesterolemia, respectively. In the present study, we evaluated the effect of rs505151 (23968A>G) polymorphism of PCSK9 over atorvastatin and ezetimibe therapies in Chilean subjects with HC. Both therapies diminished significantly total and LDL cholesterol serum levels (P<0.001). When we evaluated the response to atorvastatin, only the individuals carrying AA genotype presented a significant reduction of total cholesterol (274 vs. 231 mg/dL, p<0.001) and LDL-c levels (186 vs. 145 mg/dL, p<0.001). In summary, our data suggest that rs505151 affects lipid-lowering response to atorvastatin but does not modified therapeutic response to ezetimibe in the population investigated. Thus, this polymorphism could be a helpful genetic marker to predict the response to atorvastatin in our population.
机译:PCSK9是LDL-C的关键调节剂,增强肝脏LDLR的降解。 PCSK9中的几种功能性和功能丧失分别与高胆固醇血症(HC)和次氯化物血症相关联。在本研究中,我们评估了PCSK9对阿托伐他汀和伊替菊酯的智利HC智利对象疗法的影响。两种疗法总数明显减少,LDL胆固醇血清水平(P <0.001)。当我们评估对阿托伐他汀的响应时,只有携带AA基因型的个体呈现总胆固醇的显着降低(274与231mg / dL,P <0.001)和LDL-C水平(186 Vs.145mg / dl,P < 0.001)。总之,我们的数据表明,RS505151对阿托伐他汀的降脂反应影响降低,但在调查的人口中没有修改对欧塞蒂米的治疗反应。因此,这种多态性可能是有用的遗传标记,以预测对我们人群的阿托伐他汀的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号